Kubota Masayuki, Hirayama Yutaka, Okuyama Naoki
Department of Pediatric Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Niigata 951-8510, Japan.
Pediatr Surg Int. 2010 Oct;26(10):1037-40. doi: 10.1007/s00383-010-2664-8.
Basic fibroblast growth factor (bFGF) is a newly identified recombinant agent that promotes wound healing through an augmented neovascularization. This study examined the effect of bFGF in the treatment of perianal abscesses.
Nine consecutive males with an average age of 5.1 months (1-9 months) who presented with perianal abscess in the past 2 years were treated with bFGF (Transfermin, Kaken Co., Ltd., Tokyo, Japan). Two or three sprays of bFGF were applied to the perianal abscess two times a day.
All nine patients responded well to the bFGF treatment. Pus discharge and local swelling around the fistula subsided within a mean of 7.3 ± 1.9 days (1 SD) after the initiation of treatment. One case showed a mild relapse 7 months after treatment and the other developed a new lesion 1 month after treatment. However, these lesions also similarly disappeared after a second treatment with bFGF without a recurrence in the follow-up examinations at 11 and 10 months, respectively. The remaining seven cases have all done well without any recurrence at a mean follow-up period of 14.1 ± 3.2 months.
These results clearly indicate the usefulness of the bFGF spray as a new treatment strategy for the management of perianal abscesses.
碱性成纤维细胞生长因子(bFGF)是一种新发现的重组剂,可通过增强新血管形成来促进伤口愈合。本研究探讨了bFGF在肛周脓肿治疗中的作用。
连续9例平均年龄5.1个月(1 - 9个月)、在过去2年中出现肛周脓肿的男性患者接受了bFGF(Transfermin,日本东京嘉研株式会社)治疗。每天两次在肛周脓肿处喷洒两到三下bFGF。
所有9例患者对bFGF治疗反应良好。治疗开始后,瘘管周围的脓性分泌物和局部肿胀在平均7.3±1.9天(1个标准差)内消退。1例在治疗7个月后出现轻度复发,另1例在治疗1个月后出现新病变。然而,在分别用bFGF进行第二次治疗后,这些病变同样消失,在11个月和10个月的随访检查中均无复发。其余7例情况良好,在平均14.1±3.2个月的随访期内均无复发。
这些结果清楚地表明bFGF喷雾剂作为肛周脓肿治疗新策略的有效性。